|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0033684,
umls-concept:C0039194,
umls-concept:C0085358,
umls-concept:C0205263,
umls-concept:C0664336,
umls-concept:C1332320,
umls-concept:C1332714,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1516213,
umls-concept:C1527249,
umls-concept:C1706438,
umls-concept:C2698600
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2003-8-8
|
|
pubmed:abstractText |
The identification of tumor-associated antigens expressed by colorectal carcinoma remains one of the major goals for designing novel immunological treatments for this tumor. By using a reverse-immunology approach, we show here that the inhibitor of apoptosis protein, survivin, is immunogenic in colorectal cancer patients. In particular, we found that survivin elicited CD8(+) T cell-mediated responses in peripheral blood or in tumor-associated lymphocytes from patients at different disease stage. Colorectal carcinoma cells were recognized by survivin-specific T lymphocytes, and the survivin-specific, class-I HLA-restricted T lymphocytes were fully activated and released interleukin-2 in response to HLA/survivin-peptide complexes expressed by tumor cells. In addition to CD8-mediated responses, survivin specifically stimulated CD4+ T-cell reactivity in peripheral blood lymphocytes from the same patients, thus suggesting that a complete activation of the immune system may occur in response to this antiapoptotic protein. These findings indicate that survivin could be considered a valuable tumor-associated antigen for immune-based clinical approaches in colorectal cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0008-5472
|
|
pubmed:author |
pubmed-author:AndreolaSalvatoreS,
pubmed-author:BelliFilibertoF,
pubmed-author:CasatiChiaraC,
pubmed-author:CastelliChiaraC,
pubmed-author:CostaAuroraA,
pubmed-author:DalerbaPieroP,
pubmed-author:DehoPaolaP,
pubmed-author:GallinoGianfrancescoG,
pubmed-author:LeoErmannoE,
pubmed-author:MezzanzanicaDeliaD,
pubmed-author:ParmianiGiorgioG,
pubmed-author:RiniFrancescaF,
pubmed-author:RivoltiniLiciaL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4507-15
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12907624-Aged,
pubmed-meshheading:12907624-Amino Acid Sequence,
pubmed-meshheading:12907624-CD4-Positive T-Lymphocytes,
pubmed-meshheading:12907624-CD8-Positive T-Lymphocytes,
pubmed-meshheading:12907624-Colorectal Neoplasms,
pubmed-meshheading:12907624-Epitopes, T-Lymphocyte,
pubmed-meshheading:12907624-Female,
pubmed-meshheading:12907624-HLA-A2 Antigen,
pubmed-meshheading:12907624-Humans,
pubmed-meshheading:12907624-Inhibitor of Apoptosis Proteins,
pubmed-meshheading:12907624-Male,
pubmed-meshheading:12907624-Microtubule-Associated Proteins,
pubmed-meshheading:12907624-Middle Aged,
pubmed-meshheading:12907624-Neoplasm Proteins,
pubmed-meshheading:12907624-Peptide Fragments,
pubmed-meshheading:12907624-Transfection,
pubmed-meshheading:12907624-Tumor Cells, Cultured
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.
|
|
pubmed:affiliation |
Unit of Immunotherapy of Human Tumors, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian 1, 20133 Milan, Italy. chiara.castelli@istitutotumori.mi.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
